SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ:TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced commencement of shipments for its
next-generation t:slim X2™ Insulin Pump. The t:slim X2 Pump boasts an
advanced Bluetooth radio and is optimized for use with Tandem's recently
cleared Tandem Device Updater, designed to update software and add new
features from a personal computer as they are approved by the U.S. Food
and Drug Administration (FDA).1
The t:slim X2 Pump is the newest addition to the Company's family of
innovative insulin pumps. All Tandem pumps feature a high-contrast color
touchscreen with a streamlined, user-friendly interface. This provides
people rapid access to frequently used features, while making these
features simple to learn and simple to use.2 Each Tandem
product utilizes modern technology, such as a built-in rechargeable
battery and micro-USB port for convenient charging and fast data
Notable features of the t:slim X2 Pump include:
Up to 38% smaller than other insulin pumps3,4
Rechargeable battery, which saves hundreds of dollars in out of pocket
Durable aluminum housing
Watertight (IPX7) construction, tested to a depth of three feet for 30
Advanced Bluetooth radio, capable of communicating with compatible
devices and future technologies
Optimized for use with the Tandem Device Updater for remote software
and feature updates from a personal computer1
The t:slim X2 Pump will replace Tandem's first-generation t:slim®
Insulin Pump. The Company will continue to support current t:slim Pumps,
in addition to the t:slim G4™ and t:flex® Insulin Pumps. The t:slim X2
Pump is intended for the subcutaneous delivery of insulin, at set and
variable rates, for the management of diabetes mellitus in persons
requiring insulin, for individuals 12 years of age and greater.
For additional product and safety information, or to begin the order
process, visit www.tandemdiabetes.com/tslimX2
call (877) 801-6901, Monday - Friday between 6am and 5pm Pacific Time
About the Tandem Device Updater
The Tandem Device Updater, cleared by the FDA in July 2016, is a tool
for the remote update of Tandem insulin pump software from a personal
computer. The first use of the Tandem Device Updater is to provide
t:slim® Insulin Pumps purchased before April 2015 with a free update to
the latest software features. This updated software began shipping on
new t:slim Pumps as of April 2015 and includes a variety of product
enhancements for convenience and flexibility. Software updates and new
features for Tandem pumps are being developed for implementation through
the Tandem Device Updater as they are approved for commercial
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touch-screen simplicity. Tandem is
based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
t:slim, t:flex, and Tandem Diabetes Care are registered trademarks, and
t:slim X2 and t:slim G4 are trademarks of Tandem Diabetes Care, Inc. All
other trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things the Company's plans to complete the
development and obtain regulatory approval of future features to release
on the t:slim X2 platform as remote software updates, and the Company's
plans to utilize the Tandem Device Updater to update software and add
new features to the t:slim X2 pump from a personal computer as they are
approved by the FDA. These statements are subject to numerous risks and
uncertainties, including the Company's ability to sustain commercial
scale manufacturing of the t:slim X2 pump on a timely basis, the
Company's reliance on third-party suppliers the Company's ability to
source various product components in sufficient quantities that meet the
Company's quality requirements, the Company's ability to complete the
development of proposed software updates and new features for the t:slim
X2 pump, the Company's ability to utilize the Tandem Device Updater as
intended, the Company's ability to obtain regulatory approvals for
future products and product features generally, as well as other risks
identified in Tandem's most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q, and other documents that Tandem files
with the Securities and Exchange Commission. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date of this release. Tandem undertakes no obligation to
update or review any forward-looking statement in this press release
because of new information, future events or other factors.
1 Software updates and new features are not currently
available for the t:slim X2 Pump and are subject to future FDA
approvals. Charges may apply.
2 Schaeffer N, Parks L,
Verhoff E, et al. J Diabetes Sci Technol. March 2015.9:221-230.
38% smaller than MiniMed 630G and 670G and 25% smaller than MiniMed
530G, Animas Vibe and Omnipod System.
4 Data on file.
Tandem Diabetes Care, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005439/en/
Tandem Diabetes Care, Inc.
Susan Morrison, 858-366-6900 x7005
Source: Tandem Diabetes Care
News Provided by Acquire Media